NextCure Inc. (NASDAQ: NXTC) saw its shares nearly triple in early trading on Tuesday, July 14, 2026, after the company announced a merger agreement with privately held Avere Therapeutics, coupled with a $320 million financing package. However, the rally may be more about a potential cash distribution and contingent value rights than the headline financing number, as existing NextCure shareholders are expected to own just 1.21% of the combined company.
By 10:55 a.m. EDT, NextCure shares had surged 176.6% to $6.03, after opening at $9.22 and hitting an intraday high of $11.10. Trading volume exploded to 81.4 million shares, roughly 20 times the 4.07 million basic shares outstanding as of June 30, indicating event-driven trading rather than a settled valuation.
Deal Structure and Ownership Impact
The merger agreement sets Avere's pre-financing equity value at $250 million, with the actual financing proceeds added to its transaction value. NextCure's starting valuation of $11 million is adjusted downward based on its final net cash position relative to the deal target. As a result, the expected ownership split for NextCure shareholders drops from 1.89% before the net-cash adjustment to just 1.21%.
Of the $320 million private placement, at least $251 million (78%) consists of convertible notes and accrued interest being exchanged for equity at closing, rather than fresh cash. This means the headline financing number overstates the actual new capital infusion, with no more than $69 million coming as new cash subscriptions.
Implied Valuation and Market Reaction
Assuming the full $320 million financing closes, the disclosed ownership split implies roughly $7 million of merger value for NextCure, or about $1.72 per basic share as of June 30, before any dividend or contingent payment. At $6.03, the market was assigning about $17.6 million beyond this inferred allocation, reflecting expectations for a permitted pre-closing dividend, future contingent value rights (CVR), and the prospect that Avere commands a higher valuation post-listing.
NextCure held $29.7 million in cash, cash equivalents, and marketable securities as of March 31. The merger agreement permits a dividend only if final net cash exceeds the deal target after liabilities and transaction costs. The company also expects about $1.9 million in restructuring charges as it cuts a substantial majority of its workforce, halts new U.S. enrollment in the SIM0505 study, and opts out of further LNCB74 cost-sharing.
Contingent Value Rights and Pipeline
The CVR would give holders 90% of net proceeds from licensing, selling, or monetizing NextCure's legacy assets for two years after closing. However, the SEC filing warns there is no assurance the CVR will produce a payment, and the right is non-transferable. The legacy option is real but not cash.
Avere's lead drug, AVR-001, is an oral IL-23 receptor blocker designed for once-weekly dosing in plaque psoriasis. A global Phase 2b trial is planned for early 2027, with results expected in the first half of 2028. CEO Andrew Cheng said the financing provides a clear line of sight to potentially value-generating clinical data, but proof is still needed.
Competitive Landscape
AVR-001 faces an established benchmark: Johnson & Johnson (NYSE: JNJ) and Protagonist Therapeutics (NASDAQ: PTGX) secured U.S. approval in March 2026 for ICOTYDE, a once-daily oral IL-23 receptor antagonist, based on four Phase 3 studies involving about 2,500 patients. Avere's efficacy case so far rests on a cross-trial comparison after four weeks of Phase 1b dosing, a much lower evidence bar.
Risks and Next Steps
The merger still requires shareholder approvals, an effective registration statement, Nasdaq clearance, and at least $150 million of financing proceeds (including converted notes). Final ownership can shift with NextCure's net cash, AVR-001 could disappoint in later-stage trials, and the CVR may pay nothing. The market is betting on a package of possibilities, but the path to proof is long.
